Global Sotorasib Tablets Market: Major Trends Reshaping the Future of the Industry

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Sotorasib Tablets Industry Market Size Be by 2025?
The market for sotorasib tablets has seen a significant expansion in recent years. Forecasts project an increase from $1.71 billion in 2024 to $1.92 billion in 2025, representing a compound annual growth rate (CAGR) of 12.5%. The substantial growth during the historical period is largely due to factors such as the rising incidence of non-small cell lung cancer, heightened consciousness around targeted cancer treatments, greater implementation of precision medicine, an increased number of oncology treatment centers, and amplified government backing for cancer medications.

What's the Long-Term Growth Forecast for the Sotorasib Tablets Market Size Through 2029?
Anticipations suggest a swift expansion in the sotorasib tablets market in the upcoming years, scaling up to $3.04 billion by 2029 with a compound annual growth rate (CAGR) of 12.1%. Underpinning this forecasted growth is the escalating investment in research of KRAS inhibitors, the augmentation of sotorasib production capabilities, collaborations intensifying between biotech and pharmaceutical industries, growing demand for bespoke cancer treatments, and increasing applications of oral targeted therapies. Key trends projected for the forecast period encompass advancements in the creation of targeted therapy, evolution in methods of KRAS mutation detection, research and development investment in cancer drugs, innovation in oral cancer drug formulation, and progress in sustainable pharmaceutical manufacturing practices.

View the full report here:
https://www.thebusinessresearchcompany.com/report/sotorasib-tablets-global-market-report

What Are the Key Growth Drivers Fueling the Sotorasib Tablets Market Expansion?
The escalation in the number of cancer cases is anticipated to stimulate the expansion of the sotorasib tablets market. Cancer describes an array of diseases characterized by the unregulated growth of abnormal cells that invade tissues and have the potential to metastasize to other body parts. The surge in cancer cases can be attributed to an aging population, considering the fact that the risk of developing many types of cancer markedly increases with age, particularly for individuals aged over 65. Sotorasib tablets function by selectively and irreversibly engaging the KRAS G12C mutation, thereby permanently neutralizing the mutated protein to inhibit indiscriminate cell growth in patients suffering from advanced solid tumors, specifically non-small cell lung cancer. The World Health Organization, a Switzerland-based global organization dealing with aspects of global health policy and public health programs, noted in February 2024 that projected new cancer cases for 2050 were over 35 million, a sharp rise of 77% from the estimated 20 million cases in 2022. Consequently, the escalation in cancer incidence is accelerating the expansion of the sotorasib tablets market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28336&type=smp

What Are the Key Trends Driving Sotorasib Tablets Market Growth?
Mainstream corporations in the sotorasib tablets market are channeling their efforts into innovating new therapies such as combination treatments, aiming to enhance effectiveness and conquer resistance. Such therapies involve the co-administration of multiple drugs, targeting cancer from different angles concurrently. This method helps amplify the treatment's potency, surmount or prolong drug resistance, diminish the chances of cancer relapse, and boost overall patient prognosis and life quality. For instance, in January 2025, Amgen Inc., an American biotech firm, achieved U.S. FDA approval for sotorasib in conjunction with panitumumab for the treatment of adults suffering from KRAS G12C-mutated metastatic colorectal cancer (mCRC) who have already undergone standard chemotherapy. The FDA's approval was rooted in the Phase 3 CodeBreaK 300 study outcomes, which showed that the combined therapy more than doubled progression-free survival compared to the typical standard-of-care treatment selected by the investigator, thereby offering a significantly new therapeutic option for patients battling this complex type of cancer. Sotorasib stands as a pioneer in oral KRAS G12C inhibitors and operates by selectively targeting the mutant KRAS protein, immobilizing it in its non-active state, and consequently hindering cancer cell proliferation and signaling pathways energized by this mutation.

How Is the Sotorasib Tablets Market Segmented?
The sotorasib tablets market covered in this report is segmented as

1) By Dosage Form: 40 Milligrams (Mg) Tablets, 120 Milligrams (Mg) Tablets, 240 Milligrams (Mg) Tablets, Other Dosage Forms
2) By Patient Demographics: Adolescents, Adult, Senior Adults
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By Application: Non-Small Cell Lung Cancer, Colorectal Cancer, Other Applications
5) By End-User: Hospitals, Oncology Centers, Clinics, Other End-Users

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=28336&type=smp

Which Companies Are Leading the Charge in Sotorasib Tablets Market Innovation?
Major companies operating in the sotorasib tablets market are Amgen Inc., Ziska Pharmaceuticals Limited, Everest Pharmaceuticals Inc., Lucius Pharmaceutical Co. Ltd.

Which Regions Are Leading the Global Sotorasib Tablets Market in Revenue?
North America was the largest region in the sotorasib tablets market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sotorasib tablets report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=28336

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.